AVCJ

Taiwan's JHL Biotech raises $45m in Series C round

  • Holden Mann
  • LinkedIn  
  • Google plus  
  • Save this article  

Taiwan-based biopharmaceutical company JHL Biotech has raised a $45 million Series C round, led by an unnamed investor. Existing backer Milestone Capital also participated, along with newcomers Sungent BioVenture and Liwick Investment Management.

The company will use the funds to build new facilities at its manufacturing center in Wuhan, complete development on two proprietary chemical compounds, and expand its pre-clinical novel therapeutic portfolio, according to a release.

Founded in 2012, JHL aims to produce and market biological medicine for affordable prices through innovative methods. It also partners with global pharmaceutical companies to help them access the China market.

JHL's early backers included KPCB, CDIB, Biomark and Sequoia Capital, which contributed an undisclosed amount in 2012, before JHL's $10 million Series A round led by Burrill & Co. in 2013. Its Series B round last year, led by Milestone, was worth $35 million.

Since the Series B, the company has gained regulatory approval for its Taiwan factory and has manufactured the first batch of its debut drug for clinical trials. JHL is preparing to list on the Taiwan Emerging Stock Market and also hopes to enter the EU market by the end of 2015.

  • LinkedIn  
  • Google plus  
  • Save this article  

More on Greater China

Latest News

world-hands-globe-climate-esg
Asian GPs slow implementation of ESG policies - survey

Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...

  • GPs